RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study
I'm PortAI, I can summarize articles.
RedHill Biopharma announced positive preclinical results for opaganib combined with venetoclax in treating Chronic Lymphocytic Leukemia (CLL). The combination reduced CLL cell counts by 50% in a mouse model, suggesting opaganib's potential as an add-on therapy for venetoclax-resistant CLL. The study also showed decreased T cell counts and PD1 expression. The company has already announced these findings.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments